Infliximab-induced skin manifestations in patients with inflammatory bowel disease

Scandinavian Journal of Gastroenterology

Volumn 51, Issue 5, 2016, Pages 563-571

  Hellström, Alec Eligius ^a   Färkkilä, Martti ^a   Kolho, Kaija Leena ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Crohn's disease; drug eruption; psoriasis; tumour necrosis factor alpha; ulcerative colitis

Indexed keywords

INFLIXIMAB; GASTROINTESTINAL AGENT;

ADULT; ARTICLE; ATOPIC DERMATITIS; CROHN DISEASE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT LENTIGO; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIASIS VULGARIS; PUSTULOSIS PALMOPLANTARIS; SKIN MANIFESTATION; STRUCTURED QUESTIONNAIRE; DOSE RESPONSE; DRUG ERUPTIONS; FINLAND; INCIDENCE; INFLAMMATORY BOWEL DISEASES; INTRAVENOUS DRUG ADMINISTRATION; QUESTIONNAIRE;

ADULT; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; FEMALE; FINLAND; GASTROINTESTINAL AGENTS; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; INFUSIONS, INTRAVENOUS; MALE; PROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES;

EID: 84956725281     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2015.1125524     Document Type: Article

References (33)

1. Dignass A, Van Assche G, Lindsay JO., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010; 4: 28-62
2. Dignass A, Lindsay JO, Sturm A., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2012; 6: 991-1030
3. Van Assche G, Lewis JD, Lichtenstein GR., et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the EuropeanCrohn's and Colitis Organisation: safety. Am J Gastroenterol. 2011; 106: 1594-1602
4. Mocci G, Marzo M, Papa A., et al. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis. 2013; 7: 769-779
5. Mälkönen T, Wikström A, Heiskanen K., et al. Skin reactions during anti-TNFα therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm Bowel Dis. 2014; 20: 1309-1315
6. Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011; 52: 230-232
7. Sherlock ME, Walters T, Tabbers MM., et al. Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms. J Pediatr Gastroenterol Nutr. 2013; 56: 512-518
8. Flendrie M, Vissers WHPM, Creemers MCW., et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005; 7: R666-R676
9. Lee HH, Song IH, Friedrich M., et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosisfactor-alpha antagonists. Br J Dermatol. 2007; 156: 486-491
10. Machado NP, Torresdos Reis Neto E, Soares MRMP., et al. The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis. Clinics. 2013; 68: 1189-1196
11. Tillack C, Ehmann LM, Friedrich M., et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014; 63: 567-577
12. Denadai R, Teixeira FV, Steinwurz F., et al. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis. 2013; 7: 517-524
13. Baumgart DC, Grittner U, Steingräber A., et al. Frequency, phenotype, outcome and therapeutic impact of skin reactions following initiation of Adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis. 2011; 17: 2512-2520
14. Włodarczyk M, Sobolewska A, Wójcik B., et al. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohns disease patients. World J Gastroenterol. 2014; 20: 7019-7026
15. Huang VWM, Dhami N, Fedorak D., et al. A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels. Can J Gastroenterol. 2015; 29: 35-40
16. Fidder H, Schnitzler F, Ferrante M., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009; 58: 501-508
17. Cullen G, Kroshinsky D, Cheifetz AS., et al. Psoriasis associated with anti-tumournecrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011; 34: 1318-1327
18. Guerra I, Algaba A, Pérez-Calle JL., et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis. 2012; 6: 518-523
19. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012; 9: 496-503
20. Hernández MV, Sanmartí R, Cañete JD., et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatoid conditions with tumor necrosis factor antagonists: study using the Spanish Registry of adverse events of biological therapies in rheumatoid diseases. Arthritis Care Res. 2013; 65: 2024-2031
21. Collamer AN, Battafano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010; 40: 233-240
22. Ma HL, Napierata L, Stedman N., et al. Tumor necrosis factoralpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum. 2010; 62: 430-440
23. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009; 58: 1152-1167
24. Koga C, Kabashima K, Shiraishi N., et al. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008; 128: 2625-2630
25. Asarch A, Barak O, Loo DS., et al. Th17 cells: a new paradigm for cutaneous inflammation. J Dermatol Treat. 2008; 19: 259-266
26. Collamer AN, Guerrero KT, Henning JS., et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008; 59: 996-1001
27. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996; 14: 485-496
28. Gelfand JM, Weinsten R, Porter SB., et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005; 141: 1537-1541
29. Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol. 1982; 106: 323-330
30. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol. 1990; 85: 962-963
31. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol. 2009; 23: 561-565
32. Levine JS, Burakoff R. Extraintestinal, manifestations of inflammatory bowel disease. Gastroenterol Hepatol. 2011; 7: 235-241
33. Lolli E, Saraceno R, Calabrese E., et al. Psoriasis phenotype in inflammatory bowel disease: a case-control prospective study. J Crohns Colitis. 2015; 9: 699-707